SABS SAB Biotherapeutics
- 2.9300
- -0.0400-1.35%
SAB Biotherapeutics News
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
SAB Biotherapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
SAB Biotherapeutics Analyst Ratings
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for SAB Biotherapeutics' SAB-142 in Type 1 Diabetes Treatment Drives Buy Rating
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11
SAB Biotherapeutics Analyst Ratings
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)
Chardan Capital Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $25
SAB Biotherapeutics Analyst Ratings
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
SAB Biotherapeutics Initiated at Outperform by Oppenheimer
SAB Biotherapeutics Price Target Announced at $12.00/Share by Oppenheimer
Oppenheimer Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $12
SAB Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
Analysis
Price Target
No Data
No Data